HIMS Stock Down 50% From Peak: Buying Opportunity or Value Trap?

HIMS stock was the hottest telehealth stock on Wall Street. The stock hit $72.98 in February 2025 and analysts were falling over themselves with price target increases. Today HIMS is trading around $31 to $34. That's a 50% to 56% haircut in less than a year. The kind of loss that makes you question your stock picking abilities.

So here's the only question that matters. Is this a generational buying opportunity or are you about to catch a falling knife?

Three Disasters Hit at Exactly the Wrong Time

It wasn't one thing that killed HIMS. It was three major problems hitting simultaneously.

The FDA Killed the Golden Goose

HIMS was printing money selling compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. During the shortage, this was completely legal and wildly profitable. People wanted weight loss meds, couldn't get the brand names, and HIMS happily filled the gap at attractive prices.

Then in February 2025, the FDA removed semaglutide from its drug shortage list. The legal window for mass producing compounded versions slammed shut. The stock dropped 22% in a single trading session. HIMS had projected $725 million in weight loss revenue for 2025. That entire business segment went from goldmine to potential liability overnight.

Novo Nordisk Said We're Done Here

HIMS struck a partnership with Novo Nordisk earlier in 2025 to resell actual Wegovy to telehealth patients. This could have been the lifeline that saved the whole GLP-1 strategy. The partnership lasted exactly three months before Novo pulled out, publicly stating that HIMS failed to comply with laws prohibiting mass sales of compounded drugs. Novo has repeatedly excluded HIMS from its official partner lists since then.

Getting dumped by Big Pharma isn't just embarrassing. It's a massive red flag about how you're running your business.

Amazon Showed Up and Everyone Panicked

Amazon Pharmacy announced in early January 2026 that it would offer Wegovy at brutally competitive prices. We're talking $25 per month for customers with insurance according to CNBC. Amazon has infinite capital, 200 million plus Prime members, existing pharmacy infrastructure, and can operate on margins so thin they'd bankrupt most competitors.

Bank of America responded by slashing their price target to $29, the lowest on Wall Street.

Why Some Investors Are Still Believers

The business is still growing and it's actually profitable. HIMS brought in $1.48 billion in revenue for 2024, up 69% from 2023. Management guided for $2.3 to $2.4 billion in 2025, roughly 59% growth. And unlike most telehealth companies that burn cash, HIMS generated $174 million in EBITDA last year. In a sector where most companies are hemorrhaging cash, HIMS is profitable and growing fast.

They're diversifying as fast as they can. CEO Andrew Dudum launched Labs, a diagnostic subscription platform. They acquired Zava, a European telehealth company. They entered Canada. They're expanding beyond sexual health and dermatology. Management's 2030 target is $6.5 billion in revenue and $1.3 billion in EBITDA. If they hit even 70% of that, today's price looks silly.

Vertical integration creates real advantages. HIMS manufactures products, handles fulfillment, and controls the entire customer experience. That's harder for competitors to replicate and gives them pricing flexibility that marketplace models can't match.

The valuation has reset hard. At $31 to $34, HIMS trades around 54 times forward earnings. Still expensive, but far cheaper than at $73. The average analyst price target sits at $43.50, implying 27% to 37% upside.

Why This Could Get Worse

Regulatory risk is a ticking time bomb. HIMS faces ongoing class action lawsuits alleging they misrepresented FDA compliance on compounded GLP-1 sales. The FDA has issued warning letters to telehealth providers, including HIMS, for marketing practices the agency called false or misleading. Any serious regulatory crackdown could cut revenue by 20% to 30% almost immediately.

Margins are compressing. Third quarter 2025 showed gross margin at 77% versus analyst expectations of 78.4%. In a high volume healthcare business where you're competing on price, every percentage point matters. If HIMS competes aggressively with Amazon to maintain market share, those margins could get squeezed further.

Customer acquisition costs are rising. Bank of America specifically called out rising costs to acquire new customers as competition intensifies. You're paying more for customers while potentially cutting prices? That's how profitability disappears.

Wall Street is lukewarm. Of 14 analysts covering HIMS, eight rate it Hold, three Buy, and three Sell. The consensus is basically it's fairly valued here, which means limited upside without positive surprises.

The Real Talk on Whether You Should Buy It

HIMS at these levels is a bet for risk tolerant investors who believe three things simultaneously. First, the telehealth model wins long term despite Amazon, CVS, and Walgreens building their own platforms. Second, HIMS can successfully pivot away from GLP-1 dependency into other high margin specialties fast enough. Third, the current price reflects way too much pessimism about a business growing 59% and making money when peers burn cash.

If you believe all three, then yeah, the risk reward at $31 to $34 might be compelling. But if you're skeptical that a mid cap telehealth company can simultaneously fight Amazon, navigate hostile regulators, AND execute a major business pivot without screwing up, this might be a value trap. The 50% decline could be halfway done.

Here's What I'd Actually Do

Position sizing matters more than being right about a stock. A small speculative position, maybe 1% to 3% of your portfolio, lets you participate in potential upside without ruining your year if things go sideways.

Watch these catalysts. Q4 2025 and Q1 2026 earnings are coming soon. You want to see if margins stabilize or keep compressing. Any regulatory news from the FDA could move the stock 20% overnight. Partnership announcements that could replace the lost Novo Nordisk relationship would be huge. International expansion updates from Zava and Canada matter because that's their diversification story.

The market cut this stock in half. Whether that's an overreaction or well deserved depends entirely on execution over the next six to twelve months.

Bottom line. HIMS at $31 is a completely different risk proposition than HIMS at $73. But 50% cheaper doesn't automatically mean cheap. It just means the market is a lot more skeptical. Size your bets appropriately. Don't put money into this stock that you need for anything important. The volatility isn't over.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. HIMS stock involves significant risks including regulatory uncertainty, competitive pressures, and execution risk. Past performance does not guarantee future results.